Phase 3CompletedAge-related condition
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)
A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal Women
- Sponsor
- Bayer (Industry)
- Enrollment
- 400 enrolled
- Conditions
- Vasomotor Symptoms Associated With Menopause; Hot Flashes
- Interventions
- Elinzanetant (BAY3427080); Placebo
- Ages
- adults, older adults
- Registry
- NCT05099159, EUCTR2020-004855-34
Full record on ClinicalTrials.gov
From the registry
Researchers are looking for a better way to treat women who have hot flashes after women have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the menopause. Menopause is when women stop having a menstrual cycle, also called a period. During the menopause, the ovaries increasingly produce less sex hormones as a result of the natural ageing process and related hormonal adjustments. The decline in hormone production can lead to various symptoms which, in some cases, can have a very adverse effect on a menopausal woman's quality of life. The study treatment, elinzanetant, was developed to treat symptoms caused by hormonal changes. It works by blocking a protein called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes. There are treatments for hot flashes in women who have been through the menopause, but may cause medical problems for some people. In this study, the researchers will learn how well elinzanetant works compared to a placebo in women…
Primary outcomes
- Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD)
- Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)
- Mean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD)
- Mean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)
History
Results first posted
Last registry update
Study completion
Primary completion
Registered
Started
In the news
ConferenceBusiness Wire (opens Business Wire in a new tab)
Bayer presents post hoc sleep analysis of menopause drug elinzanetant’s two pivotal trials
The OASIS-1 and OASIS-2 subanalysis examined PROMIS questionnaire scores in women with moderate-to-severe vasomotor symptoms; Bayer presented the findings at the Menopause Society’s annual meeting.
